AstraZeneca stomach cancer drug cuts death risk by 53% in late-stage study

AstraZeneca's Sonesitatug vedotin reduced the risk of death by 53% in second- and later-line CLDN18.2-positive advanced gastric/GEJ cancers in the Phase 3 CLARITY-Gastric01 trial, meeting the primary overall survival endpoint.

Detected & updated continuously · Source: Nebula